Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.
about
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsRecent advances and novel treatment paradigms in acute lymphocytic leukemiaCharacterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced ImmunogenicityAntibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsA recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapyThe use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsAddition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention.Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.Treating multiple sclerosis with monoclonal antibodies: a 2010 update.Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.The link between VLA-4 and JC virus reactivation.Immunotherapeutic approaches for cancer therapy: An updated review.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes.The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity.Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.Complement in cancer: untangling an intricate relationship.In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis.Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent CytotoxicityComplement as a Biological Tool to Control Tumor Growth
P2860
Q26852287-A043220C-4251-4962-B004-7EBFCA30ED98Q28078076-E0684BED-57CA-4321-9F08-6F8AF5ED3595Q28548044-4D7DF583-9CFE-494A-9549-4EF934AD03C3Q30276243-D76B86DB-EF00-4264-BCC7-15C4790FDBE6Q30356145-B2AE0B64-76B8-4417-AF18-397961B5B2C9Q30405847-E075859B-55F4-482B-B39A-C594047AF7C5Q30421637-92095E6C-4ED1-4C8B-B9CB-A7A87F71F285Q30959165-10904241-DAC0-4BA0-A6E2-17B0E856746DQ33407700-A187C0CD-6ECD-4B24-B9C1-C22E813AE419Q33576327-5D689F78-78A1-4330-BF69-0335CD0309F3Q33733443-05853E52-CC4D-4D33-B50C-E0033C5DB67DQ35569491-8D95C301-D230-4931-BC15-6C0E36FBFBAFQ37448352-34692CC4-62AD-46F2-A48B-2D04F9D418F9Q37559275-A407D5E1-AB2A-4698-A38D-9C7605BC0400Q37737305-AF5964AD-B25C-4ED1-9293-D7AC93546D83Q37866150-A5701FF0-955D-48B8-8805-736923E02FEBQ37965603-EA0AE13A-3C35-462D-A785-EC895178DFC2Q38388102-495BB15E-51B7-4B64-AA8F-16A01C833963Q38808823-98C05BA5-1FA3-470D-8193-298EE8669009Q39474069-67C38969-1070-4B46-B3D4-C852C5CF9E39Q39646209-A8622386-6A2F-4DEA-A391-8271A9C5AED9Q41966008-FB2D5A4C-67EE-4059-9630-B15296DD9255Q43249169-E50EC2A1-64B4-48C2-BBCD-1D78B2FD1033Q50049007-D8C2C169-8FC9-4A5A-B62B-4931BA7C5A2BQ50640571-7CEA2508-DE77-4D09-94F7-2C09DF8FD206Q51774121-F1631D61-2AB1-4430-A9BE-3DF9A9ADD01DQ54125905-FCEE0838-14E9-4B68-9875-07E0B3733811Q54146573-80FBC246-5866-4EA1-94B3-6C00CFB5080DQ56908538-42DAF1F3-C924-469B-93D7-71FAAD483BD7Q57492005-F6E3A3AA-3737-4B51-86A7-0B8143015217
P2860
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Direct and complement dependen ...... ith alemtuzumab and rituximab.
@en
type
label
Direct and complement dependen ...... ith alemtuzumab and rituximab.
@en
prefLabel
Direct and complement dependen ...... ith alemtuzumab and rituximab.
@en
P2093
P2860
P921
P1433
P1476
Direct and complement dependen ...... ith alemtuzumab and rituximab.
@en
P2093
Betsy R LaPlant
Charla R Secreto
Clive S Zent
Diane F Jelinek
Nancy D Bone
Neil E Kay
Renee C Tschumper
Tait D Shanafelt
Timothy G Call
P2860
P304
P356
10.1016/J.LEUKRES.2008.05.014
P577
2008-06-27T00:00:00Z